These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34871157)

  • 21. Age-Related Differences in Immunological Responses to SARS-CoV-2.
    Wong LSY; Loo EXL; Kang AYH; Lau HX; Tambyah PA; Tham EH
    J Allergy Clin Immunol Pract; 2020; 8(10):3251-3258. PubMed ID: 32861856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19.
    Gusev E; Sarapultsev A; Solomatina L; Chereshnev V
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures.
    Hui KPY; Cheung MC; Perera RAPM; Ng KC; Bui CHT; Ho JCW; Ng MMT; Kuok DIT; Shih KC; Tsao SW; Poon LLM; Peiris M; Nicholls JM; Chan MCW
    Lancet Respir Med; 2020 Jul; 8(7):687-695. PubMed ID: 32386571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview.
    Rathore JS; Ghosh C
    Pathog Dis; 2020 Aug; 78(6):. PubMed ID: 32840560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2.
    Xia H; Shi PY
    J Interferon Cytokine Res; 2020 Dec; 40(12):543-548. PubMed ID: 33337934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
    Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
    Front Immunol; 2020; 11():1880. PubMed ID: 32973779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.
    Long SW; Olsen RJ; Christensen PA; Bernard DW; Davis JJ; Shukla M; Nguyen M; Saavedra MO; Yerramilli P; Pruitt L; Subedi S; Kuo HC; Hendrickson H; Eskandari G; Nguyen HAT; Long JH; Kumaraswami M; Goike J; Boutz D; Gollihar J; McLellan JS; Chou CW; Javanmardi K; Finkelstein IJ; Musser JM
    mBio; 2020 Oct; 11(6):. PubMed ID: 33127862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pulmonary innate immune response in Sars-cov-2 infection].
    Bottino E; Ponce AA
    Rev Fac Cien Med Univ Nac Cordoba; 2022 Mar; 79(1):33-42. PubMed ID: 35312259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.
    Beeraka NM; Sadhu SP; Madhunapantula SV; Rao Pragada R; Svistunov AA; Nikolenko VN; Mikhaleva LM; Aliev G
    Front Immunol; 2020; 11():552925. PubMed ID: 33072093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.
    Vetter P; Eberhardt CS; Meyer B; Martinez Murillo PA; Torriani G; Pigny F; Lemeille S; Cordey S; Laubscher F; Vu DL; Calame A; Schibler M; Jacquerioz F; Blanchard-Rohner G; Siegrist CA; Kaiser L; Didierlaurent AM; Eckerle I
    mSphere; 2020 Nov; 5(6):. PubMed ID: 33177214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating angiotensin-converting enzyme 2-mediated SARS-CoV-2 entry across species.
    Zhang HL; Li YM; Sun J; Zhang YY; Wang TY; Sun MX; Wang MH; Yang YL; Hu XL; Tang YD; Zhao J; Cai X
    J Biol Chem; 2021; 296():100435. PubMed ID: 33610551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
    McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics.
    Ebrahimi N; Aslani S; Babaie F; Hemmatzadeh M; Hosseinzadeh R; Joneidi Z; Mehdizadeh Tourzani Z; Pakravan N; Mohammadi H
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107082. PubMed ID: 33068865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Zhang C; Zhou C; Shi L; Liu G
    Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.
    Nguyen-Contant P; Embong AK; Kanagaiah P; Chaves FA; Yang H; Branche AR; Topham DJ; Sangster MY
    mBio; 2020 Sep; 11(5):. PubMed ID: 32978311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases.
    Carsetti R; Zaffina S; Piano Mortari E; Terreri S; Corrente F; Capponi C; Palomba P; Mirabella M; Cascioli S; Palange P; Cuccaro I; Milito C; Zumla A; Maeurer M; Camisa V; Vinci MR; Santoro A; Cimini E; Marchioni L; Nicastri E; Palmieri F; Agrati C; Ippolito G; Porzio O; Concato C; Onetti Muda A; Raponi M; Quintarelli C; Quinti I; Locatelli F
    Front Immunol; 2020; 11():610300. PubMed ID: 33391280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.